The endothelin system and its role in pulmonary arterial hypertension (PAH)

Thorax

Volumn 60, Issue 6, 2005, Pages 443-444

  Pepke Zaba, J ^a   Morrell, N W ^b  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; PROSTACYCLIN; SITAXSENTAN;

ANEMIA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; INTIMA; LIVER TOXICITY; LUNG ARTERY; LUNG RESISTANCE; LUNG VASOCONSTRICTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ENDOTHELINS; HUMANS; HYPERTENSION, PULMONARY; RECEPTORS, ENDOTHELIN;

EID: 20444478388     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2004.031724     Document Type: Editorial

References (17)

1. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease. Ann Intern Med 1991;114:464-9.
2. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in me lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
3. A-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 1994;266:H1327-1.
4. Miyauchi T, Yorikane R, Sakai S, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993;73:887-97.
5. Chen S-J, Chen Y-F, Opgenorth TJ, et al. The orally active nonpeptide endothelin A receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodelling in Sprague-Dawley rots. J Cardiovasc Pharmacol 1997;29:713-2.
6. Davie N, Haleen SJ, Upton PD, et al. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:398-405.
7. Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002;105:1034-6.
8. Channick R, Simonneau G, Sitbon O, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;3581119-23.
9. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
10. Barst R, Ivy D, Widlitz AC, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372-82.
11. Silbon O, Gressin V, Speich R, et al. Bosentan in pulmonary arterial hypertension associated with HIV infection. Eur Respir J 2003;22:563.
12. McLaughlin V, Sitbon O, Rubin LJ, et al. The effect of first-line bosentan on survival of patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2003;167:A442.
13. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860-8.
14. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.
15. Frost A, Langleben D, Hill NS, et al. 6MW as an efficacy endpoint in PAH clinical trials: demonstration of a ceiling effect. Am J Respir Crit Care Med 2004;169:A176.
16. Rubin LJ, Galie N, Badesch BD, et al. Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2004;(in press),
17. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: Breathe-2. Eur Respir J 2004;24:353-9.